<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897269</url>
  </required_header>
  <id_info>
    <org_study_id>656/BVTD-HDDD</org_study_id>
    <nct_id>NCT04897269</nct_id>
  </id_info>
  <brief_title>Progesterone Supplementation on Women Having Low Progesterone Levels on Transfer Day</brief_title>
  <official_title>Effectiveness of Progesterone Supplementation for Women Having Low Progesterone Levels on the Day of Frozen Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tu Du Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tu Du Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare clinical pregnancy rates between two groups of&#xD;
      women who have progesterone levels below 10 ng/mL on the day of frozen embryo transfer: group&#xD;
      1 (vaginal micronized progesterone supplemented with progesterone intramuscular 50 mg per&#xD;
      day) and group 2 (vaginal micronized progesterone with no supplementation)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial Design:&#xD;
&#xD;
      Single center, longitudinal, randomized, interventional, controlled, pharmacological study,&#xD;
      enrolling women attending clinical Centers of medically assisted reproduction (ART).&#xD;
&#xD;
      The study protocol consists in the record of all the diagnostic and clinical outcome&#xD;
      parameters, according to clinical practice, for the following patient cohorts:&#xD;
&#xD;
        -  The patients who are undergoing frozen embryo transfers with blastocyst or cleavage&#xD;
           stage embryos and have progesterone levels below 10 ng/mL on the day of embryo transfer&#xD;
&#xD;
        -  Study groups&#xD;
&#xD;
             -  Group supplemented with progesterone intramuscular 50 mg per day until the day of&#xD;
                beta-hcg testing (Intervention group);&#xD;
&#xD;
             -  Group with no supplementation (Control group).&#xD;
&#xD;
                  -  Endometrial cycle is started with estradiol valerate dose of 4 mg to 8 mg per&#xD;
                     day, the patients then are appointed to have ultrasound scan of their&#xD;
                     endometrium every 3 to 7 days and the dose of estradiol may be increased to 16&#xD;
                     mg per day maximum depends on the thickness of endometrium; when their&#xD;
                     endometrium reach 8 mm or higher and duration of endometrial preparation is ≥&#xD;
                     12 days, the embryo transfer will be planned and transvaginal progesterone are&#xD;
                     prescribed according to the day of transfer.&#xD;
&#xD;
                  -  If this is the first cycle of embryo transfer and she is &lt; 35 years of age, 1&#xD;
                     grade 1 embryo is transferred, otherwise 2 embryos are transferred.&#xD;
&#xD;
                  -  In the morning of embryo-transferred day, all patients will have their blood&#xD;
                     tested for progesterone levels, if their levels below 10 ng/mL, they will be&#xD;
                     recruited into the study and randomized into two groups.&#xD;
&#xD;
                  -  In the study group, the patients will be prescribed with intramuscular&#xD;
                     progesterone supplemetation 50 mg + 800mg vaginal micronized progesterone per&#xD;
                     day for 14 days, until the day of beta-hcg testing.&#xD;
&#xD;
                  -  In the control group, the patients will continue their regular medications&#xD;
                     (800mg vaginal micronized progesterone per day) until the day of beta-hcg&#xD;
                     testing without any progesterone supplementation.&#xD;
&#xD;
                  -  If the beta-hcg test is positive, the patients will be continued their&#xD;
                     prescriptions depending on study or control group as mentioned above till 7&#xD;
                     weeks of pregnancy when the fetal heart can be confirmed, then the patients&#xD;
                     will be followed up till 11 - 12 weeks of pregnancy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who have progesterone levels below 10 ng/mL on the day of embryo transfer will be randomized into 2 groups:&#xD;
Those who will be supplemented with intramuscular progesterone 50mg per day till day of beta-hcg testing&#xD;
Those who will continue their regular medications</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>week 11 - 14 of pregnancy</time_frame>
    <description>defined as the pregnancy completed 11 - 14 weeks of gestation and having vital fetus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>3 weeks after embryo transfer</time_frame>
    <description>the percentage of embryos which successfully undergo implantation compared to the number of embryos transferred in a given period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <description>beta-hCG test is positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>3 weeks after embryo transfer</time_frame>
    <description>pregnancy when fetal heart can be confirmed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">824</enrollment>
  <condition>Assisted Reproductive Technology</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the control group, the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg two times per day for 14 days, without any progesterone supplementation. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the interventional group,the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg x 2 per day for 14 days, supplemented with intramuscular progesterone (Progesterone 25mg/ml) 25 mg x 2 at one time per day for 14 days. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Progesterone supplementation</intervention_name>
    <description>This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergone ART with frozen embryo transfer, blastocyst or cleavaged stage&#xD;
             embryo transfer, from 18-45 years of age&#xD;
&#xD;
          -  Normal BMI&#xD;
&#xD;
          -  HRT for Endometrial preparation in FET cycles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Oocyte donor cycles&#xD;
&#xD;
          -  Surrogacy&#xD;
&#xD;
          -  IVM&#xD;
&#xD;
          -  PGT&#xD;
&#xD;
          -  Abnormal Uterine (firbroids 0 -&gt; 3 according to FIGO classification, polyp,&#xD;
             adenomyosis, congenital malformation)&#xD;
&#xD;
          -  Uterus fibroids type 4,5 (Figo classification) &gt; 4cm&#xD;
&#xD;
          -  History of recurrent implantation failure&#xD;
&#xD;
          -  Endometrial thickness &lt;7mm on the day of ET&#xD;
&#xD;
          -  Cesarean scar defect (isthmocele)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>We want to investigate on the pregnancy outcome, therefore only female patients will be recruited</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chau TM Le</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infertility, Tu Du Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chau TM Le, PhD</last_name>
    <phone>+84908429006</phone>
    <email>dr.lethiminhchau@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anh Q Nguyen, Master</last_name>
    <phone>+84976137562</phone>
    <email>dr.anhquocnguyen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Infertility of Tu Du hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chau TM Le, PhD</last_name>
      <phone>0084908429006</phone>
      <email>dr.lethiminhchau@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anh Q Nguyen, MMSc</last_name>
      <phone>0084976137562</phone>
      <email>dr.anhquocnguyen@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tu K Duong, MMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anh Q Nguyen, MMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thinh P Ong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chau TM Le, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matheus Roque, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlo Alviggi, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Cédrin-Durnerin I, Isnard T, Mahdjoub S, Sonigo C, Seroka A, Comtet M, Herbemont C, Sifer C, Grynberg M. Serum progesterone concentration and live birth rate in frozen-thawed embryo transfers with hormonally prepared endometrium. Reprod Biomed Online. 2019 Mar;38(3):472-480. doi: 10.1016/j.rbmo.2018.11.026. Epub 2019 Jan 5.</citation>
    <PMID>30642638</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaggiotti-Marre S, Martinez F, Coll L, Garcia S, Álvarez M, Parriego M, Barri PN, Polyzos N, Coroleu B. Low serum progesterone the day prior to frozen embryo transfer of euploid embryos is associated with significant reduction in live birth rates. Gynecol Endocrinol. 2019 May;35(5):439-442. doi: 10.1080/09513590.2018.1534952. Epub 2018 Dec 26.</citation>
    <PMID>30585507</PMID>
  </results_reference>
  <results_reference>
    <citation>Labarta E, Mariani G, Holtmann N, Celada P, Remohí J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod. 2017 Dec 1;32(12):2437-2442. doi: 10.1093/humrep/dex316. Erratum in: Hum Reprod. 2018 Jan 1;33(1):178.</citation>
    <PMID>29040638</PMID>
  </results_reference>
  <results_reference>
    <citation>Volovsky M, Pakes C, Rozen G, Polyakov A. Do serum progesterone levels on day of embryo transfer influence pregnancy outcomes in artificial frozen-thaw cycles? J Assist Reprod Genet. 2020 May;37(5):1129-1135. doi: 10.1007/s10815-020-01713-w. Epub 2020 Feb 10.</citation>
    <PMID>32043182</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tu Du Hospital</investigator_affiliation>
    <investigator_full_name>Le Thi Minh Chau</investigator_full_name>
    <investigator_title>MD, MMSc, PhD, Head of Infertility department of Tu Du hospital</investigator_title>
  </responsible_party>
  <keyword>low progesterone levels</keyword>
  <keyword>progesterone supplementation</keyword>
  <keyword>clinical pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

